We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
InMode (INMD) Moves 6% Higher: Will This Strength Last?
Read MoreHide Full Article
InMode (INMD - Free Report) shares ended the last trading session 6% higher at $76.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.2% gain over the past four weeks.
InMode extended its rally for the third consecutive day, driven by the optimism surrounding the growing demand of its minimally invasive and innovative hands-free proprietary electrosurgical bipolar radiofrequency (RF) platforms. This can be attributed to rising customer adoption and recently introduced Morpheus8 product. Market is also upbeat about the company’s record fourth-quarter and full-year 2020 revenue performance, with the fourth-quarter sales registering year-over-year growth of 60% and full-year sales delivering an increase of 32% from the year-ago period.
Price and Consensus
This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.49 per share in its upcoming report, which represents a year-over-year change of +63.3%. Revenues are expected to be $51.08 million, up 26.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For InMode, the consensus EPS estimate for the quarter has been revised 7.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INMD going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
InMode (INMD) Moves 6% Higher: Will This Strength Last?
InMode (INMD - Free Report) shares ended the last trading session 6% higher at $76.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.2% gain over the past four weeks.
InMode extended its rally for the third consecutive day, driven by the optimism surrounding the growing demand of its minimally invasive and innovative hands-free proprietary electrosurgical bipolar radiofrequency (RF) platforms. This can be attributed to rising customer adoption and recently introduced Morpheus8 product. Market is also upbeat about the company’s record fourth-quarter and full-year 2020 revenue performance, with the fourth-quarter sales registering year-over-year growth of 60% and full-year sales delivering an increase of 32% from the year-ago period.
Price and Consensus
This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.49 per share in its upcoming report, which represents a year-over-year change of +63.3%. Revenues are expected to be $51.08 million, up 26.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For InMode, the consensus EPS estimate for the quarter has been revised 7.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INMD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>